Some detailed articles on specific MPN treatments are outlined below.
All MPNs
Polycythemia vera and Essential thrombocythemia
These include information about when to start treatment, and evidence on efficacy of Hydroxycarbamide (hydroxyurea) versus Interferon Alpha (pegasys).
- Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project, Biomedicines, 2023
- Final results from the large PROUD-PV trial and its extension CONTINUATION-PV (over 6 years)
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment, ‘Leukemia’, 2023 - Real-world treatments and thrombotic events in polycythemia vera patients in the USA, ‘Annals of Hematology’, 2023
- Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b, ‘Leukemia’, 2022
- Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival, Leukemia, 2021
- Interferons in MPNs, a conversation with an MPN specialist, 2022 – excellent video, courtesy of MPN Advocacy and Education International.
- Interferon induced retinopathy, Continuing Education Activity, (National Library of Medicine), 2022
- Basis of Hematocrit Treatment Guideline for PV: Cardiovascular Events and the Intensity of Treatment in Polycythaemia Vera, ‘NEJM’, 2013
Myelofibrosis
- Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group, Letter, Leukemia, 2024
- Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib, Letter in Blood, 2024
- Management of Patients with Early Myelofibrosis: A Discussion of Best Practices, Current Hematologic Malignancy Reports, 2024
- Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy, Leukemia and Lymphoma, 2023
- Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety, Journal of Hematology and Oncology, 2023
- Defining ruxolitinib failure and transition to next-line therapy for patients with myelofibrosis: A modified Delphi panel consensus study, ‘Future Oncol’. 2023.
- Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany, Journal of Cancer Research and Clinical Oncology, 2023
- Momelotinib Long-Term Safety and Survival in Myelofibrosis: Integrated Analysis of Phase 3 Randomized-Controlled Trials, Blood Advances, 2023
- Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study, The Lancet, 2023
- Future of Jak inhibition in myelofibrosis, 2022 (detailed video discussion from MPN experts courtesy of MPN Hub)
Myelofibrosis Stem Cell Transplant information
- Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis, Haematologica. 2023
- Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms:
A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, AJH, 2023 - Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis, AJH, 2022
- Survival following allogeneic transplant in patients with myelofibrosis
ALL MPNs
Management of MPN in pregnant patients
- Best practice recommendations for the management of MPN in pregnant patients, courtesy of MPN Hub, 2021
(Please note that these are not Australian guidelines and local Australian practices may differ.) - How interferon works in MPN patients, November 2022, courtesy of MPN Advocacy and Education International
This is a video presentation and Q and A session with Dr Gaby Hobbs, MPN specialist, Clinical Director of Leukemia Service at Massachusetts General Hospital and Assistant Professor at Harvard Medical School. This is wide-ranging and includes considerations physicians take into account about using interferon in pregnancy (35 mins in).
Possible future treatments via targeted therapies – may not yet be available in Australia
- Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial, ‘Journal of Clinical Oncology’, 2023
